(33) validated SAA as a potential biomarker for evaluating response to golimumab in RA patients but did not found clinically relevant correlation between baseline SAA levels and clinical improvement at week 24 of golimumab therapy. The gene discussed is SAA1; the disease is rheumatoid arthritis.